LinkedIn Profile

Access Catalyst Biosciences historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:cbio 43979 Mar 17th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 17th, 2024 12:04AM Mar 17th, 2024 12:04AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 16th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 15th, 2024 10:46PM Mar 16th, 2024 06:34PM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 15th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 14th, 2024 11:49PM Mar 15th, 2024 08:21AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 14th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 13th, 2024 10:45PM Mar 14th, 2024 11:43AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 13th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 12th, 2024 10:43PM Mar 13th, 2024 10:14AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 12th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 11th, 2024 10:45PM Mar 12th, 2024 02:38PM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 11th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 10th, 2024 10:51PM Mar 11th, 2024 09:36AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 10th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 9th, 2024 09:56PM Mar 9th, 2024 09:56PM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 9th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 8th, 2024 09:52PM Mar 9th, 2024 02:51PM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences
nasdaq:cbio 43979 Mar 8th, 2024 12:00AM Catalyst Biosciences 7.0K 16.00 Open Mar 7th, 2024 10:19PM Mar 8th, 2024 10:36AM Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Open Protease engineering and proteases in hemostasis Open 611 Gateway Blvd South San Francisco CA US 94080 Catalyst Biosciences

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.